BioDelivery Sciences posts net loss in 2013 as research costs rise

Posted by David Bracken on March 18, 2014 

BioDelivery Sciences International reported late last week that it swung to a net loss last year as the Raleigh company ramped up its research and development spending.

The company had a net loss of 57.1 million, or $1.51 per share, compared with net income of $1.7 million, or 5 cents per share, in 2012.

Revenue was $11.4 million, compared with $54.5 million in 2012. The decline was the result of the company receiving two one-time milestone payments and deferred revenue from the launch of one of its products in Europe.

Research and development expenses increased from $35.4 million in 2012 to $53.3 million last year. The increase was attributed to additional costs associated with the development of Bunavail, a treatment for opioid dependence, and BEMA Buprenorphine, the company’s experimental treatment for chronic pain.

In February, BioDelivery Sciences raised $60 million by selling a block of shares to a group of institutional investors. The proceeds are to pay for the commercialization of Bunavail.

The company has filed a new drug application for Bunavail and expects to hear back from the Food and Drug Administration on June 7. BioDelivery Sciences also expects to begin enrolling patients in Phase 3 trials of its Clonidine Topical Gel, a treatment for painful diabetic neuropathy, a condition that afflicts some people suffering from diabetes. The company signed a licensing deal to develop the drug last year.

As of Feb. 28, BioDelivery Sciences had $89.8 million in cash, compared with $63.2 million at the end of 2012.

The company’s shares closed Tuesday at $9.04, up 17 cents. The stock is up more than 53 percent this year.

Staff writer David Bracken

News & Observer is pleased to provide this opportunity to share information, experiences and observations about what's in the news. Some of the comments may be reprinted elsewhere in the site or in the newspaper. We encourage lively, open debate on the issues of the day, and ask that you refrain from profanity, hate speech, personal comments and remarks that are off point. Thank you for taking the time to offer your thoughts.

Commenting FAQs | Terms of Service